Preparing the published article.
Virtual Incision: MIRA Miniaturized Surgical Robotics and Indication Expansion
Lincoln-based developer of the MIRA surgeon-controlled system. Review its compact architecture, colectomy and benign hysterectomy labeling, staged availability and software service history.
Company and platform
Virtual Incision is headquartered in Lincoln, Nebraska, and develops the MIRA Surgical System for minimally invasive soft-tissue surgery. Its miniaturized approach aims to reduce the equipment footprint associated with robotic assistance. MIRA is the company’s platform, not a separate supplier; a hospital evaluation should cover the complete system and the support needed for its intended specialty.
Compact equipment and surgeon control
The manufacturer describes an approximately two-pound minibot with instrument arms and an articulating camera, accompanied by a surgeon console and equipment cart. The surgeon controls the instruments and camera from the console. The small robot weight does not describe the mass or space requirements of the entire installation, and portability does not establish autonomous surgical capability.
U.S. indications and patient limits
FDA granted De Novo authorization DEN230025 in February 2024 for colon mobilization during minimally invasive colectomy in specified adults. Clearance K260817, dated 20 August 2026, adds minimally invasive benign subtotal or total hysterectomy, with or without salpingectomy. Labeling includes height and weight limits and additional uterine-size and BMI limits for hysterectomy. Qualified clinicians must consult the complete current labeling and manual.
Clearance and commercial availability
In its 25 August 2026 announcement, Virtual Incision reported U.S. commercial availability for colectomy while placing gynecology availability in a later phase with timing still to be announced. Procurement teams should therefore confirm the offered indication, configuration and delivery schedule. A U.S. regulatory milestone does not establish availability or authorization in Hong Kong or another market.
Software service history
FDA recall Z-1905-2025 concerned three specified MIRA-CAP-110 units running console software 4.0.3 and a latency-related motion-display issue. The FDA record reviewed on 11 September 2026 lists the recall as Completed. For an offered system, request its software version, serial and service records, and evidence of applicable corrections; this historical record should not be generalized to every MIRA configuration.
Clinical evidence and evaluation scope
The manufacturer’s safety information distinguishes device evaluation from cancer survival, recurrence or underlying-disease outcomes. Assess published evidence against the intended patient population and local clinical pathway instead of assuming superior outcomes from miniaturization. The hospital’s clinical and engineering teams should review training, compatibility, reprocessing instructions, contingency arrangements and follow-up responsibilities together.
Commercial and operational review
Request a quotation separating capital equipment, single-use instruments, servicing, training and ongoing support. Confirm operating-room layout, storage and turnaround requirements with the proposed configuration. Record who handles updates, equipment faults and replacement components. A purchasing decision should include local support capacity, recurring costs and a documented handover to the hospital team.